Verona Pharma的呼吸道药物进入第3阶段试验,获得“Buy”评级,价格目标很高。 Verona Pharma receives a "Buy" rating with a high price target, as its respiratory drug enters Phase 3 trials.

Verona Pharma是一家开发呼吸道疾病治疗的生物制药公司, 得到沃尔夫研究的“优异”评分, Verona Pharma, a biopharmaceutical company developing treatments for respiratory diseases, received an "outperform" rating from Wolfe Research with a $170 price target, suggesting a 79.74% upside. 其他分析家也给予正面评价,导致达成共识的“Buy”评级,平均价格目标为107.36美元。 Other analysts have also given positive ratings, leading to a consensus "Buy" rating with a $107.36 average price target. 该公司的主要产品恩西芬,正在治疗COPD,喘和囊性纤维化等疾病的第三期试验中. The company's main product, ensifentrine, is in Phase 3 trials for COPD, asthma, and cystic fibrosis.